Whilst the pharmaceutical and biotech industries may continue to be under a positive spotlight due to continuing innovations, particularly relating to the pandemic response, there is still an area in which the industries are lagging behind…
Research and development (R&D).
Whether this issue is in terms of the speed, success, or productivity of clinical development, one thing remains clear – regardless of high R&D investments, biopharma is struggling with how to positively change the trajectory of R&D.
So, how can R&D projects in pharma and biotech be streamlined, and where are the key issues?